-
公开(公告)号：US10464951B2
公开(公告)日：2019-11-05
申请号：US15354239
申请日：2016-11-17
Applicant: Intrexon Corporation
Inventor： Sheela K. Chellappan , Robert E. Hormann , Inna Shulman
Abstract: The present disclosure provides boron-containing diacylhydrazines having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, and R5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.
-
公开(公告)号：US20180079759A1
公开(公告)日：2018-03-22
申请号：US15354239
申请日：2016-11-17
Applicant: Intrexon Corporation
Inventor： Sheela K. CHELLAPPAN , Robert E. Hormann , Inna Shulman
CPC classification number: C07F5/025 , C07F5/027 , C07F5/04 , C07F7/0803
Abstract: The present disclosure provides boron-containing diacylhydrazines having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, and R5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.
-
公开(公告)号：US09127024B2
公开(公告)日：2015-09-08
申请号：US14212526
申请日：2014-03-14
Applicant: Intrexon Corporation
Inventor： Sheela K. Chellappan , Robert E. Hormann , Inna Shulman
CPC classification number: C07F5/025 , C07F5/027 , C07F5/04 , C07F7/0803
Abstract: The present disclosure provides boron-containing diacylhydrazines having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, and R5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.
Abstract translation: 本公开提供了具有式I的含硼二酰基肼及其药学上可接受的盐和溶剂化物，其中R1，R2，R3，R4和R5如说明书所述定义。 本公开还提供了含硼二酰肼的用途是基于蜕皮激素受体的诱导型基因表达系统。 因此，本公开对于诸如基因治疗，疾病治疗，蛋白质和抗体的大规模生产，基于细胞的筛选测定，功能基因组学，蛋白质组学，代谢组学和调控转基因生物中的性状等应用是有用的，其中 基因表达水平是理想的。
-
公开(公告)号：US10851119B2
公开(公告)日：2020-12-01
申请号：US16580343
申请日：2019-09-24
Applicant: Intrexon Corporation
Inventor： Sheela K. Chellappan , Robert E. Hormann , Inna Shulman
Abstract: The present disclosure provides boron-containing diacylhydrazines having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, and R5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.
-
公开(公告)号：US20140274954A1
公开(公告)日：2014-09-18
申请号：US14212526
申请日：2014-03-14
Applicant: Intrexon Corporation
Inventor： Sheela K. CHELLAPPAN , Robert E. Hormann , Inna Shulman
CPC classification number: C07F5/025 , C07F5/027 , C07F5/04 , C07F7/0803
Abstract: The present disclosure provides boron-containing diacylhydrazines having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, and R5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.
Abstract translation: 本公开提供了具有式I的含硼二酰基肼及其药学上可接受的盐和溶剂化物，其中R1，R2，R3，R4和R5如说明书所述定义。 本公开还提供了含硼二酰肼的用途是基于蜕皮激素受体的诱导型基因表达系统。 因此，本公开对于诸如基因治疗，疾病治疗，蛋白质和抗体的大规模生产，基于细胞的筛选测定，功能基因组学，蛋白质组学，代谢组学和调控转基因生物中的性状等应用是有用的，其中控制 基因表达水平是理想的。
-
Patent Agency Ranking
公开(公告)号：US20200157122A1
公开(公告)日：2020-05-21
申请号：US16580343
申请日：2019-09-24
Applicant: Intrexon Corporation
Inventor： Sheela K. Chellappan , Robert E. Hormann , Inna Shulman
Abstract: The present disclosure provides boron-containing diacylhydrazines having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, and R5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.
-
公开(公告)号：US10570158B2
公开(公告)日：2020-02-25
申请号：US15915415
申请日：2018-03-08
Applicant: Intrexon Corporation
Inventor： Ray A. James , Sheela K. Chellappan , Robert E. Hormann
Abstract: The present disclosure provides boron-containing diacylhydrazines having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein A, R4, and R5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.
-
公开(公告)号：US20160083403A1
公开(公告)日：2016-03-24
申请号：US14855646
申请日：2015-09-16
Applicant: Intrexon Corporation
Inventor： Ray A. JAMES , Sheela K. Chellappan , Robert E. Hormann
IPC: C07F5/02 , C07D263/06 , C07C243/38
CPC classification number: C07F5/025 , A01N37/28 , A01N55/08 , A61K31/69 , A61K45/06 , C07D263/06 , A61K2300/00
Abstract: The present disclosure provides boron-containing diacylhydrazines having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein A, R4, and R5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.
Abstract translation: 本公开提供了具有式I的含硼二酰基肼及其药学上可接受的盐和溶剂合物，其中A，R4和R5如说明书所述定义。 本公开还提供了含硼二酰肼的用途是基于蜕皮激素受体的诱导型基因表达系统。 因此，本公开对于诸如基因治疗，疾病治疗，蛋白质和抗体的大规模生产，基于细胞的筛选测定，功能基因组学，蛋白质组学，代谢组学和调控转基因生物中的性状等应用是有用的，其中 基因表达水平是理想的。
-
公开(公告)号：US20150322092A1
公开(公告)日：2015-11-12
申请号：US14805837
申请日：2015-07-22
Applicant: Intrexon Corporation
Inventor： Sheela K. CHELLAPPAN , Robert E. Hormann , Inna Shulman
IPC: C07F5/02
CPC classification number: C07F5/025 , C07F5/027 , C07F5/04 , C07F7/0803
Abstract: The present disclosure provides boron-containing diacylhydrazines having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, and R5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.
Abstract translation: 本公开提供了具有式I的含硼二酰基肼及其药学上可接受的盐和溶剂化物，其中R1，R2，R3，R4和R5如说明书所述定义。 本公开还提供了含硼二酰肼的用途是基于蜕皮激素受体的诱导型基因表达系统。 因此，本公开对于诸如基因治疗，疾病治疗，蛋白质和抗体的大规模生产，基于细胞的筛选测定，功能基因组学，蛋白质组学，代谢组学和调控转基因生物中的性状等应用是有用的，其中控制 基因表达水平是理想的。
-
公开(公告)号：US20180201628A1
公开(公告)日：2018-07-19
申请号：US15915415
申请日：2018-03-08
Applicant: Intrexon Corporation
Inventor： Ray A. James , Sheela K. Chellappan , Robert E. Hormann
Abstract: The present disclosure provides boron-containing diacylhydrazines having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein A, R4, and R5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.025 seconds)
